• 1
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 5770.
  • 2
    Folkman J, Klagsbrun M. Vascular physiology: a family of angiogenic peptides. Nature 1987; 329: 67172.
  • 3
    Fidler IJ, Radinsky R. Genetic control of cancer metastasis. J Natl Cancer Inst 1990; 82: 16668.
  • 4
    Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo-stellate cells. Proc Natl Acad Sci U S A 1989; 86: 731115.
  • 5
    Risau W, Drexler H, Mironov V, Smits A, Siegbahn A, Funa K, Heldin CH. Platelet-derived growth factor is angiogenic in vivo. Growth Factors 1992; 7: 26166.
  • 6
    Sato N, Beitz JG, Kato J, Yamamoto M, Clark JW, Calabresi P, Raymond A, Frackelton AR Jr. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 1993; 142: 111930.
  • 7
    Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, Klagsbrun M. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 1984; 223: 129699.
  • 8
    Bussolino F, Wang JM, Defilippi P, Turrini F, Sanavio F, Edgell CJ, Aglietta M, Arese P, Mantovani A. Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 1989; 337: 47173.
  • 9
    Bussolino F, Ziche M, Wang JM, Alessi D, Morbidelli L, Cremona O, Bosia A, Marchisio PC, Mantovani A. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest 1991; 87: 98695.
  • 10
    Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989; 58: 575606.
  • 11
    Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992; 59: 11565.
  • 12
    Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocrin Rev 1997; 18: 2645.
  • 13
    Schwartz SM, Liaw L. Growth control and morphogenesis in the development and pathology of arteries. J Cardiovasc Pharmacol 1993; 21: 3149.
  • 14
    Siemeister G, Martiny-Baron G, Marme D. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Cancer Metastasis Rev 1998; 17: 24148.
  • 15
    Tischer E, Gospodarowicz D, Mitchell R, Silva M, Schilling J, Lau K, Crisp T, Fiddes JC, Abraham JA. Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun 1989; 165: 1198206.
  • 16
    Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5: 180614.
  • 17
    Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 130609.
  • 18
    Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12: 30324.
  • 19
    Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N. The carboxyl-terminal domain (111–165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996; 271: 778895.
  • 20
    Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992; 189: 82431.
  • 21
    Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 8691.
  • 22
    Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996; 73: 93134.
  • 23
    Denhart BC, Guidi AJ, Tognazzi K, Dvorak HF, Brown LF. Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Lab Invest 1997; 77: 65964.
  • 24
    Johnsson A, Heldin CH, Wasteson A, Westermark B, Deuel TF, Huang JS, Seeburg PH, Gray A, Ullrich A, Scrace G. The c-sis gene encodes a precursor of the B chain of platelet-derived growth factor. Embo J 1984; 3: 92128.
  • 25
    Beck L, D'Amore PA. Vascular development: cellular and molecular regulation. Faseb J 1997; 11: 36573.
  • 26
    Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 1993; 53: 455054.
  • 27
    Kawai T, Hiroi S, Torikata C. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest 1997; 77: 43136.
  • 28
    Skobe M, Fusenig NE. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc Natl Acad Sci U S A 1998; 95: 105055.
  • 29
    Williams ME, Quesenberry PJ. Hematopoietic growth factors. Hematol Pathol 1992; 6: 10524.
  • 30
    Hamilton JA, Piccoli DS, Cebon J, Layton JE, Rathanaswani P, McColl SR, Leizer T. Cytokine regulation of colony-stimulating factor (CSF) production in cultured human synovial fibroblasts. II. Similarities and differences in the control of interleukin-1 induction of granulocyte-macrophage CSF and granulocyte-CSF production. Blood 1992; 79: 141319.
  • 31
    Berdel WE, Danhauser-Riedl S, Steinhauser G, Winton EF. Various human hematopoietic growth factors (interleukin-3, GM-CSF, G- CSF) stimulate clonal growth of nonhematopoietic tumor cells. Blood 1989; 73: 8083.
  • 32
    Guillaume T, Sekhavat M, Rubinstein DB, Hamdan O, Symann ML. Transcription of genes encoding granulocyte-macrophage colony- stimulating factor, interleukin 3, and interleukin 6 receptors and lack of proliferative response to exogenous cytokines in nonhematopoietic human malignant cell lines. Cancer Res 1993; 53: 313944.
  • 33
    Lahm H, Wyniger J, Hertig S, Yilmaz A, Fischer JR, Givel JC, Odartchenko N. Secretion of bioactive granulocyte-macrophage colony-stimulating factor by human colorectal carcinoma cells. Cancer Res 1994; 54: 370002.
  • 34
    Mueller MM, Fusenig NE. Constitutive expression of G-CSF and GM-CSF in human skin carcinoma cells with functional consequence for tumor progression. Int J Cancer 1999; 83: 78089.
  • 35
    Mueller MM, Herold-Mende CC, Riede D, Lange M, Steiner HH, Fusenig NE. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am J Pathol 1999; 155: 155767.
  • 36
    Noda I, Fujieda S, Ohtsubo T, Tsuzuki H, Tanaka N, Sunaga H, Saito H. Granulocyte-colony-stimulating factor enhances invasive potential of human head-and-neck-carcinoma cell lines. Int J Cancer 1999; 80: 7884.
  • 37
    Vokes EE, Hara DJ, McEvilly JM. Intensified concomitant chemotherapy with and without Filgrastim for poor-prognosis head and neck cancer. J Clin Oncol 1994; 12: 235159.
  • 38
    Mayordomo JI, Rivera F, Diaz-Puente MT, Lianes P, Colomer R, Lopez-Brea M, Lopez E, Paz-Ares L, Hitt R, Garcia-Ribas I. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony stimulating factors. J Natl Cancer Inst 1995; 87: 80308.
  • 39
    Bennett CL, Smith TJ, Week JC, Bredt AB, Feinglass J, Fetting JH, Hillner BE, Willner MR, Winn RJ. Use of hematopoietic colony stimulating factors: the American Society of Clinical Oncology Survey. J Clin Oncol 1996; 14: 251120.
  • 40
    Rosier J-F, Scalliet P. Use of hematopoietic growth factors in radiation therapy. Prog Growth Factors 1997; 3: 36.
  • 41
    Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, Flentje M, Eckel HE, Mueller RP. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50: 116171.
  • 42
    Botta M, Manetti F, Corelli F. Fibroblast growth factors and their inhibitors. Curr Pharm Des 2000; 6: 1897924.
  • 43
    Knox JJ, Moore MJ. Treatment of hormone refractory prostate cancer. Semin Urol Oncol 2001; 19: 20211.
  • 44
    Mesters RM, Padro T, Bieker R, Steins M, Kreuter M, Goner M, Kelsey S, Scigalla P, Fiedler W, Buchner T, Berdel WE. STable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001; 98: 2413.
  • 45
    Petruzzelli GJ, Benefield J, Taitz AD, Fowler S, Kalkanis J, Scobercea S, West D, Young MR. Heparin-binding growth factor(s) derived from head and neck squamous cell carcinomas induce endothelial cell proliferation. Head Neck 1997; 19: 57682.
  • 46
    Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999; 5: 136979.
  • 47
    Herold-Mende C, Seiter S, Born AI, Patzelt E, Schupp M, Zöller J, Bosch FX, Zöller M. Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck. J Pathol 1996; 179: 6673.
  • 48
    Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular switch. Cancer Res 2001; 61: 273643.
  • 49
    Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res 1997; 3: 16777.
  • 50
    Schmidt NO, Westphal M, Hagel C, Ergun S, Stavrou D, Rosen EM, Lamszus K. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1997; 84: 108.
  • 51
    Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, Taniguchi T, Tominaga T. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996; 77: 110106.
  • 52
    Mueller MM, Peter W, Mappes M, Huelsen A, Steinbauer H, Boukamp P, Vaccariello M, Garlick J, Fusenig NE. Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am J Pathol 2001; 159: 156779.
  • 53
    Gleich LL, Srivastava L, Gluckman JL. Plasma platelet-derived growth factor: preliminary study of a potential marker in head and neck cancer. Ann Otol Rhinol Laryngol 1996; 105: 71012.
  • 54
    Zhang JZ, Maruyama K, Ono I, Kaneko F. Production and secretion of platelet-derived growth factor AB by cultured human keratinocytes: regulatory effects of phorbol 12- myristate 13-acetate, etretinate, 1,25-dihydroxyvitamin D3, and several cytokines. J Dermatol 1995; 22: 30509.
  • 55
    Tsukuda M, Nagahara T, Mikami Y, Yago T, Matsuda H, Yanoma S. A tumor cell line producing granulocyte colony-stimulating factor and an immune suppressive factor. Biotherapy 1993; 6: 21723.
  • 56
    Hayashi E, Rikimaru K, Nagayama M. Simultaneous production of G- and M-CSF by an oral cancer cell line and the synergistic effects on associated leucocytosis. Eur J Cancer B Oral Oncol 1995; 31B: 32327.
  • 57
    Matsuo K, Ishibashi Y, Kobayashi I, Ozeki S, Ohishi M, Tange T, Hirata J, Kiyoshima T, Sakai H. New human oral squamous carcinoma cell line and its tumorigenic subline producing granulocyte colony-stimulating factor. Jpn J Cancer Res 1994; 85: 125762.
  • 58
    Benefield J, Petruzzelli GJ, Fowler S, Taitz A, Kalkanis J, Young MR. Regulation of the steps of angiogenesis by human head and neck squamous cell carcinomas. Invasion Metastasis 1996; 16: 291301.
  • 59
    Eisma RJ, Spiro JD, Kreutzer DL. Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous cell carcinoma. Laryngoscope 1999; 109: 68793.
  • 60
    Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma: association with angiogenesis and tumor progression. Cancer 1997; 79: 20613.
  • 61
    Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S, Imamura M. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 1998; 77: 170409.
  • 62
    Mineta H, Miura K, Ogino T, Takebayashi S, Misawa K, Ueda Y, Suzuki I, Dictor M, Borg A, Wennerberg J. Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br J Cancer 2000; 6: 77581.
  • 63
    Tomita T, Fujii M, Tokumaru Y, Imanishi Y, Kanke M, Yamashita T, Ishiguro R, Kanzaki J, Kameyama K, Otani Y. Granulocyte-macrophage colony-stimulating factor upregulates matrix metalloproteinase-2 (MMP-2) and membrane type-1 MMP (MT1-MMP) in human head and neck cancer cells. Cancer Lett 2000; 156: 8391.
  • 64
    Segawa K, Ueno Y, Kataoka T. In vivo tumor growth enhancement by granulocyte colony-stimulating factor. Jpn J Cancer Res 1991; 82: 44047.